Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 15/20 | 0.45 |
| ▸ | FEN1 | P39748 | 15/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | KIT | P10721 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1703319 | 0.90 | MET (0.40) | ALOX5APFEN1CYP3A4NPC1JAK2 | |
| SCHEMBL1702674 | 0.88 | CYP3A4 (0.45) | ALOX5APFEN1CYP3A4NPC1JAK2 | |
| SCHEMBL1702697 | 0.88 | CYP3A4 (0.38) | ALOX5APFEN1CYP3A4NPC1JAK2 | |
| SCHEMBL16508269 | 0.86 | ALOX5AP (0.45) | ALOX5APFEN1CYP3A4NPC1JAK2 | |
| SCHEMBL3771679 | 0.85 | KIT (0.40) | ALOX5APFEN1KIT | |
| SCHEMBL1703193 | 0.78 | SGK1 (0.40) | ALOX5APFEN1CYP3A4NPC1JAK2 | |
| SCHEMBL16508276 | 0.76 | MET (0.40) | ALOX5APFEN1CYP3A4NPC1JAK2 | |
| SCHEMBL1702792 | 0.76 | CYP3A4 (0.45) | CYP3A4KIT | |
| SCHEMBL1702649 | 0.75 | MET (0.35) | CYP3A4NPC1JAK2RAB9A | |
| SCHEMBL1542618 | 0.74 | CYP3A4 (0.41) | CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2440528-B1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2014-10-08 | — | — | EP | claimed |
| US-20100311760-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | DE VICENTE FIDALGO JAVIER | 2010-12-09 | — | — | US | claimed |
| EP-2440528-B1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2014-10-08 | — | — | EP | disclosed |
| US-8026253-B2 | Quinoline inhibitors of HCV polymerase | ROCHE PALO ALTO LLC (US) | 2011-09-27 | — | — | US | disclosed |
| WO-2010142656-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-12-16 | — | — | WO | disclosed |
| US-20100311760-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | DE VICENTE FIDALGO JAVIER | 2010-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311760-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | EIF2AK2, XDH, GTF3C4 | ALOX5AP 3898/4885FEN1 2189/4885CYP3A4 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.